β,β-Dimethylacrylshikonin Induces Apoptosis in Melanoma Cell Lines by NOXA Upregulation

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Melanoma is an aggressive skin cancer with high metastasis and poor prognosis.
• Tumor mutational profile, particularly BRAF and NRAS mutations, impacts survival and therapy.
• No efficient therapies currently exist for NRAS-mutated or late-stage melanoma.

Purpose of the Study:

• To investigate the therapeutic potential of β,β-dimethylacrylshikonin (DMAS) in melanoma.
• To evaluate DMAS effects on melanoma cell lines with diverse mutational profiles.
• To validate findings in preclinical in vivo models.

Main Methods:

• Assessed DMAS effects on cell viability, apoptosis, and gene/protein expression in five melanoma cell lines.
• Utilized NOXA knockdown experiments to confirm apoptosis pathways.
• Validated efficacy in vivo using xenograft models.

Main Results:

• DMAS significantly reduced melanoma cell viability in a dose- and time-dependent manner.
• DMAS induced caspase-3-dependent apoptosis mediated by NOXA upregulation.
• Demonstrated tumor regression and necrosis in vivo.
• Showed successful treatment of BRAF and NRAS-mutated melanoma cell lines both in vitro and in vivo.

Conclusions:

• DMAS exhibits significant anti-melanoma activity, including against BRAF and NRAS-mutated lines.
• NOXA-dependent apoptosis is a key mechanism of DMAS action in melanoma.
• DMAS represents a promising therapeutic candidate for further investigation in melanoma treatment.